C4 Therapeutics Celebrates a Major Collaboration Milestone
C4 Therapeutics, Inc. (C4T) has achieved a significant milestone in its journey as a clinical-stage biopharmaceutical company. The firm recently delivered its second development candidate to Biogen, resulting in a remarkable $8 million milestone payment. This accomplishment highlights C4T's dedication to advancing the field of targeted protein degradation science.
Delivery of the Groundbreaking Degrader Candidate
In announcing this success, Andrew Hirsch, the president and CEO of C4 Therapeutics, expressed his enthusiasm for delivering a highly effective, brain-penetrant, orally bioavailable BiDAC™ degrader candidate. This development is particularly noteworthy as it aligns with Biogen's mission to discover and create innovative therapies that aim to improve patient outcomes.
Collaboration and Achievements
Since 2018, C4 Therapeutics and Biogen have built a collaborative framework where C4T contributes its expertise in targeted protein degradation. In this vital partnership, Biogen leverages its extensive scientific knowledge and drug development capabilities. It is impressive to see C4T not only reaching milestones but also making meaningful contributions to medicine through these collaborations.
Harnessing the TORPEDO™ Platform
The successes of C4 Therapeutics can be largely credited to its proprietary TORPEDO™ platform. This innovative technology has shown remarkable potential in designing and optimizing small-molecule medicines aimed at addressing challenging diseases. Since its inception in 2015, C4T has successfully discovered and advanced several development candidates, including the two significant candidates delivered to Biogen, showcasing the platform's effectiveness.
Future Prospects in Oncology
C4 Therapeutics is making notable progress in targeted oncology programs, focusing on developing therapies that utilize the body's natural protein recycling system. These degrader medicines are engineered to swiftly eliminate disease-causing proteins, potentially overcoming drug resistance and targeting previously undruggable proteins. Their approach holds promise for significant improvements in patient care and outcomes.
About C4 Therapeutics
C4 Therapeutics is at the cutting edge of biopharmaceutical innovation, driven by a mission to provide advanced therapies that transform the lives of patients. The company's steadfast commitment and scientific expertise in targeted protein degradation continue to produce positive results in its clinical studies.
Contact Information
For additional inquiries regarding C4 Therapeutics, interested individuals can reach out to:
Investor Relations:
Courtney Solberg
Senior Manager
Email: CSolberg@c4therapeutics.com
Media:
Loraine Spreen
Senior Director, Corporate Communications & Patient Advocacy
Email: LSpreen@c4therapeutics.com
Frequently Asked Questions
What milestone did C4 Therapeutics achieve?
C4 Therapeutics delivered its second development candidate to Biogen, leading to an $8 million milestone payment.
What technology does C4 Therapeutics use?
The company's innovative TORPEDO™ platform is utilized for developing small-molecule medicines targeting difficult diseases.
Who is responsible for clinical development of the delivered candidates?
Biogen is responsible for all future clinical development and commercialization of the candidates delivered under the collaboration.
How many development candidates has C4 delivered to Biogen?
C4 Therapeutics has successfully delivered two development candidates to Biogen under their collaboration.
What is the focus of C4 Therapeutics?
C4 Therapeutics focuses on advancing targeted protein degradation science to create transformative medications for patients.
